Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
113 shown of 2,346 total abstracts
  1. Abstract 61122026-09-01 · 16:45 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with RCC
    E. Winer, M. Krop · Mayo Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  2. Abstract 68652026-09-03 · 14:15 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-340
    S. Tolaney, M. Krop, S. Antonia, et al. · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  3. Abstract 60462026-09-04 · 15:45 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-847 study)
    A. Spira, S. Tolaney, M. Reck, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  4. Abstract 63692026-09-04 · 13:45 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-625
    T. Mok, M. Krop · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  5. Abstract 61122026-09-02 · 15:45 CT · E450
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-135 study)
    F. Andre, J. Brahmer · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  6. Abstract 64542026-09-04 · 19:30 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-906 study)
    E. Winer, T. Mok · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  7. Abstract 62752026-09-05 · 16:00 CT · S100A
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-830
    H. Rugo, T. Mok · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  8. Abstract LBA4007LBA2026-09-05 · 14:30 CT · S100A
    KEYNOTE-609: Keytruda (pembrolizumab) maintenance in RCC
    H. Borghaei, C. Saura, F. Andre · Stanford Cancer Institute
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  9. Abstract 64182026-09-04 · 20:30 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-887
    R. Herbst, S. Tolaney, P. Schmid · Dana-Farber Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  10. Abstract 66062026-09-02 · 18:30 CT · S406
    KEYNOTE-616: Keytruda (pembrolizumab) maintenance in RCC
    R. Herbst, H. Rugo, C. Saura · Chinese University of Hong Kong
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  11. Abstract 67822026-09-01 · 13:45 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-767
    G. Curigliano, S. Tolaney, M. Reck, et al. · Massachusetts General Hospital
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  12. Abstract 63612026-09-01 · 16:45 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-888
    N. Rizvi, J. Cortes, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  13. Abstract 69772026-09-02 · 21:00 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-980
    S. Peters, H. Rugo, G. Curigliano, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  14. Abstract 65652026-09-04 · 13:30 CT · Hall B1
    CheckMate-310: Opdivo (nivolumab) neoadjuvant in RCC
    T. Mok, H. Borghaei, G. Curigliano, et al. · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  15. Abstract 67542026-09-02 · 13:30 CT · S406
    Quality of life outcomes with Keytruda in patients with RCC
    H. Rugo, M. Krop, L. Paz-Ares, et al. · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  16. Abstract 61802026-09-04 · 18:45 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-764
    J. Brahmer, M. Krop · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  17. Abstract 69582026-09-04 · 20:30 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in RCC
    F. Andre, T. Mok · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  18. Abstract 60732026-09-05 · 20:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-569 study)
    S. Peters, M. Krop, S. Tolaney, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  19. Abstract 63252026-09-05 · 13:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 2L for RCC: KEYNOTE-507
    A. Spira, M. Krop, G. Curigliano, et al. · MD Anderson Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  20. Abstract 67422026-09-04 · 20:45 CT · E450
    Long-term follow-up of Keytruda neoadjuvant for RCC: KEYNOTE-815
    J. Brahmer, S. Modi, G. Curigliano · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  21. Abstract 66512026-09-02 · 14:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-913 study)
    C. Saura, M. Krop · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  22. Abstract 61742026-09-02 · 20:00 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in RCC
    F. Andre, C. Robert, E. Winer, et al. · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  23. Abstract 67302026-09-02 · 16:30 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-465
    J. Brahmer, P. Schmid · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  24. Abstract 66492026-09-02 · 14:00 CT · Arie Crown Theater
    CheckMate-184: Opdivo (nivolumab) adjuvant in RCC
    F. Andre, P. Schmid · Peter MacCallum Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  25. Abstract 67892026-09-05 · 19:00 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-843 study)
    N. Rizvi, L. Paz-Ares · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  26. Abstract 61142026-09-04 · 21:45 CT · Hall B1
    CheckMate-356: Opdivo (nivolumab) neoadjuvant in RCC
    G. Curigliano, S. Tolaney, E. Winer, et al. · Chinese University of Hong Kong
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  27. Abstract 67362026-09-03 · 19:00 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-111
    L. Paz-Ares, F. Andre, J. Cortes, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  28. Abstract 69842026-09-03 · 14:30 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-656
    P. Schmid, G. Curigliano, J. Cortes, et al. · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  29. Abstract 64952026-09-03 · 13:00 CT · S100A
    Long-term follow-up of Keytruda maintenance for RCC: KEYNOTE-577
    C. Saura, N. Rizvi, E. Winer · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  30. Abstract 68442026-09-05 · 20:00 CT · S100A
    CheckMate-77: Opdivo (nivolumab) 2L in RCC
    F. Andre, G. Curigliano, R. Herbst, et al. · Chinese University of Hong Kong
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  31. Abstract 61402026-09-03 · 19:15 CT · S406
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-567 study)
    M.C. Garassino, F. Andre, H. Borghaei · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  32. Abstract 67862026-09-05 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Opdivo adjuvant for RCC: CheckMate-333
    T. Mok, G. Curigliano · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  33. Abstract 65372026-09-05 · 18:45 CT · S100A
    Long-term follow-up of Keytruda maintenance for RCC: KEYNOTE-121
    N. Rizvi, T. Mok, J. Cortes, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  34. Abstract TPS80332026-09-02 · 16:30 CT · S100A
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-565
    C. Saura, R. Herbst, M. Reck, et al. · Institut Gustave Roussy
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  35. Abstract 67372026-09-01 · 15:45 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-54 study)
    S. Antonia, G. Curigliano, S. Modi · Royal Marsden Hospital
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  36. Abstract 66322026-09-05 · 16:45 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-547
    M. Reck, J. Brahmer, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  37. Abstract 64252026-09-04 · 21:30 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-387
    M.C. Garassino, E. Winer, H. Borghaei, et al. · Mayo Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  38. Abstract 60402026-09-04 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-69 study)
    G. Curigliano, C. Saura · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  39. Abstract 68882026-09-05 · 18:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-958
    L. Paz-Ares, G. Curigliano, C. Saura, et al. · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  40. Abstract 65592026-09-02 · 18:15 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-717 study)
    J. Cortes, S. Tolaney, S. Peters, et al. · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  41. Abstract 64612026-09-03 · 18:00 CT · S406
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-450
    R. Herbst, H. Borghaei · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  42. Abstract 61172026-09-04 · 21:45 CT · Hall B1
    KEYNOTE-398: Keytruda (pembrolizumab) 2L in RCC
    C. Robert, H. Borghaei · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  43. Abstract 64802026-09-02 · 16:00 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-270 study)
    C. Saura, N. Rizvi, C. Robert, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  44. Abstract 60042026-09-01 · 19:45 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-565 study)
    S. Peters, R. Herbst, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  45. Abstract LBA4044LBA2026-09-01 · 13:45 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-753
    M.C. Garassino, M. Reck, L. Paz-Ares, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  46. Abstract 64432026-09-01 · 14:30 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-177
    S. Modi, S. Tolaney, G. Curigliano · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  47. Abstract 65492026-09-04 · 13:45 CT · E450
    CheckMate-44: Opdivo (nivolumab) 3L+ in RCC
    M. Reck, S. Antonia · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  48. Abstract TPS80472026-09-05 · 16:00 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-721
    S. Antonia, C. Saura · Mayo Clinic
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  49. Abstract 69292026-09-02 · 20:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-950 study)
    S. Peters, C. Saura, H. Borghaei, et al. · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  50. Abstract 66042026-09-01 · 19:45 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-181
    A. Spira, M.C. Garassino, M. Reck, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  51. Abstract 63602026-09-03 · 14:30 CT · E450
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-128 study)
    C. Saura, E. Winer, M.C. Garassino, et al. · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  52. Abstract 61712026-09-02 · 14:45 CT · E450
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-81 study)
    P. Schmid, H. Rugo, J. Cortes · National Cancer Center Japan
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  53. Abstract 66442026-09-01 · 16:45 CT · S406
    CheckMate-488: Opdivo (nivolumab) neoadjuvant in RCC
    C. Saura, S. Antonia, S. Tolaney, et al. · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  54. Abstract 65912026-09-03 · 16:45 CT · Hall B1
    KEYNOTE-15: Keytruda (pembrolizumab) 1L in RCC
    M. Reck, T. Mok, P. Schmid · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  55. Abstract 61202026-09-02 · 18:30 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-520 study)
    P. Schmid, R. Herbst · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  56. Abstract 67872026-09-03 · 18:00 CT · Hall B1
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-380
    S. Tolaney, J. Brahmer, J. Cortes, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  57. Abstract 61852026-09-04 · 20:45 CT · E450
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-51 study)
    H. Rugo, R. Herbst, E. Winer · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  58. Abstract 60162026-09-03 · 19:15 CT · S100A
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-40
    S. Modi, G. Curigliano · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  59. Abstract 61642026-09-01 · 15:30 CT · E450
    KEYNOTE-203: Keytruda (pembrolizumab) maintenance in RCC
    M. Reck, F. Andre · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  60. Abstract TPS80592026-09-05 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-586 study)
    A. Spira, M.C. Garassino, N. Rizvi · UCSF Helen Diller Family Comprehensive Cancer Center
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  61. Abstract 69832026-09-03 · 14:30 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-548 study)
    P. Schmid, H. Borghaei · MD Anderson Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  62. Abstract 63642026-09-02 · 16:00 CT · S100A
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-288
    C. Saura, C. Robert, S. Antonia · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  63. Abstract 68752026-09-01 · 14:00 CT · S406
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-658
    C. Robert, H. Rugo, F. Andre, et al. · Royal Marsden Hospital
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  64. Abstract 61812026-09-01 · 20:15 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-332
    J. Brahmer, M.C. Garassino, P. Schmid, et al. · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  65. Abstract LBA4064LBA2026-09-04 · 21:15 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-932
    M.C. Garassino, C. Saura · Peter MacCallum Cancer Centre
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  66. Abstract 69882026-09-02 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-496 study)
    C. Saura, P. Schmid, N. Rizvi, et al. · Karolinska Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  67. Abstract e120662026-09-02 · 18:15 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-768 study)
    S. Peters, S. Modi, M. Krop · Stanford Cancer Institute
    Publication OnlyGenitourinary Cancer—Kidney/Bladder📄🖼️
  68. Abstract 66092026-09-04 · 20:30 CT · S100A
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-248
    N. Rizvi, H. Rugo, F. Andre, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  69. Abstract TPS80682026-09-04 · 20:15 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-921
    S. Antonia, P. Schmid, J. Brahmer, et al. · National Cancer Center Japan
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  70. Abstract TPS80692026-09-05 · 20:00 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-770
    L. Paz-Ares, S. Modi, E. Winer, et al. · Royal Marsden Hospital
    Trials in Progress Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  71. Abstract LBA4070LBA2026-09-04 · 14:30 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-679
    S. Antonia, S. Peters · Stanford Cancer Institute
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  72. Abstract 65102026-09-03 · 14:45 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-408
    S. Tolaney, T. Mok · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  73. Abstract 61772026-09-05 · 13:30 CT · Hall B1
    CheckMate-16: Opdivo (nivolumab) adjuvant in RCC
    T. Mok, R. Herbst · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  74. Abstract 68592026-09-05 · 21:30 CT · Arie Crown Theater
    KEYNOTE-330: Keytruda (pembrolizumab) 3L+ in RCC
    J. Cortes, C. Robert · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  75. Abstract 63262026-09-03 · 20:30 CT · E450
    Long-term follow-up of Keytruda adjuvant for RCC: KEYNOTE-241
    G. Curigliano, J. Cortes, S. Tolaney, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  76. Abstract 60692026-09-03 · 16:15 CT · E450
    KEYNOTE-351: Keytruda (pembrolizumab) 3L+ in RCC
    M. Reck, M.C. Garassino, S. Peters, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  77. Abstract 65472026-09-05 · 18:00 CT · Arie Crown Theater
    KEYNOTE-723: Keytruda (pembrolizumab) adjuvant in RCC
    M. Krop, S. Peters · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  78. Abstract 68202026-09-03 · 18:30 CT · S406
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-221
    S. Modi, S. Peters, J. Brahmer · Cleveland Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  79. Abstract 66942026-09-05 · 21:45 CT · S100A
    CheckMate-677: Opdivo (nivolumab) maintenance in RCC
    S. Antonia, C. Saura, J. Cortes · Peter MacCallum Cancer Centre
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  80. Abstract 63292026-09-03 · 19:00 CT · E450
    Long-term follow-up of Opdivo maintenance for RCC: CheckMate-935
    J. Cortes, S. Antonia · Institut Gustave Roussy
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  81. Abstract LBA4080LBA2026-09-01 · 20:15 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-575
    S. Peters, N. Rizvi, H. Borghaei, et al. · Vall d'Hebron Institute of Oncology
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  82. Abstract e120812026-09-01 · 13:00 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-711 study)
    S. Peters, H. Rugo, H. Borghaei · Memorial Sloan Kettering Cancer Center
    Publication OnlyGenitourinary Cancer—Kidney/Bladder📄🖼️
  83. Abstract 68372026-09-01 · 15:15 CT · S100A
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-985
    P. Schmid, F. Andre · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  84. Abstract LBA4083LBA2026-09-01 · 14:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-457 study)
    A. Spira, S. Tolaney, S. Antonia, et al. · Institut Gustave Roussy
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  85. Abstract 69612026-09-04 · 19:45 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-667
    N. Rizvi, C. Saura · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  86. Abstract 63132026-09-04 · 19:45 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-260 study)
    G. Curigliano, S. Antonia, S. Peters, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  87. Abstract 66672026-09-03 · 19:45 CT · E450
    CheckMate-494: Opdivo (nivolumab) neoadjuvant in RCC
    R. Herbst, T. Mok, F. Andre, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  88. Abstract 64952026-09-02 · 18:45 CT · S406
    Long-term follow-up of Keytruda maintenance for RCC: KEYNOTE-177
    P. Schmid, E. Winer, J. Brahmer, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  89. Abstract 62062026-09-01 · 18:00 CT · S100A
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-292
    S. Modi, N. Rizvi, S. Peters, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  90. Abstract 67882026-09-05 · 13:30 CT · S406
    KEYNOTE-840: Keytruda (pembrolizumab) neoadjuvant in RCC
    C. Saura, J. Brahmer, T. Mok, et al. · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  91. Abstract 64562026-09-02 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-541 study)
    M.C. Garassino, T. Mok · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  92. Abstract LBA4091LBA2026-09-02 · 15:30 CT · Arie Crown Theater
    Long-term follow-up of Opdivo maintenance for RCC: CheckMate-746
    C. Robert, H. Borghaei, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  93. Abstract 63882026-09-04 · 19:15 CT · S406
    CheckMate-313: Opdivo (nivolumab) adjuvant in RCC
    L. Paz-Ares, H. Borghaei, M. Reck, et al. · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  94. Abstract 69962026-09-01 · 13:45 CT · S406
    CheckMate-977: Opdivo (nivolumab) 2L in RCC
    S. Peters, C. Robert · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  95. Abstract 62802026-09-02 · 21:15 CT · S406
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-1 study)
    M.C. Garassino, S. Peters, S. Antonia · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  96. Abstract 68782026-09-02 · 19:00 CT · S100A
    KEYNOTE-177: Keytruda (pembrolizumab) neoadjuvant in RCC
    M. Krop, S. Peters, M.C. Garassino · University of Chicago
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  97. Abstract 68372026-09-05 · 16:45 CT · E450
    Long-term follow-up of Opdivo 3L+ for RCC: CheckMate-312
    M. Reck, R. Herbst, J. Brahmer, et al. · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  98. Abstract 60932026-09-04 · 14:30 CT · Hall B1
    KEYNOTE-48: Keytruda (pembrolizumab) neoadjuvant in RCC
    A. Spira, C. Robert, S. Peters, et al. · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  99. Abstract 63222026-09-04 · 16:00 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-358 study)
    C. Saura, J. Cortes, F. Andre, et al. · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  100. Abstract LBA4099LBA2026-09-05 · 21:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-314 study)
    P. Schmid, S. Modi, A. Spira · Mayo Clinic
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  101. Abstract 63302026-09-02 · 15:15 CT · S100A
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-904 study)
    J. Brahmer, S. Antonia · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  102. Abstract 62092026-09-04 · 18:15 CT · E450
    CheckMate-156: Opdivo (nivolumab) 2L in RCC
    M. Krop, E. Winer, F. Andre, et al. · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  103. Abstract 61892026-09-02 · 20:00 CT · Hall B1
    Long-term follow-up of Keytruda 2L for RCC: KEYNOTE-606
    S. Tolaney, M. Reck, H. Borghaei · Mayo Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  104. Abstract 65102026-09-02 · 16:15 CT · Hall B1
    KEYNOTE-397: Keytruda (pembrolizumab) 3L+ in RCC
    R. Herbst, C. Robert, J. Brahmer, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  105. Abstract 62212026-09-05 · 15:30 CT · S100A
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-346
    J. Cortes, S. Modi · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  106. Abstract 65462026-09-04 · 21:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-989 study)
    P. Schmid, H. Rugo, S. Peters, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  107. Abstract 61542026-09-04 · 21:45 CT · E450
    KEYNOTE-182: Keytruda (pembrolizumab) 3L+ in RCC
    H. Rugo, S. Peters, N. Rizvi, et al. · Chinese University of Hong Kong
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  108. Abstract 66172026-09-03 · 16:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-793 study)
    J. Brahmer, C. Robert, S. Peters, et al. · National Cancer Center Japan
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  109. Abstract 64052026-09-02 · 18:00 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-56
    C. Robert, H. Borghaei · Mayo Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  110. Abstract 67292026-09-01 · 14:30 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-608
    C. Robert, M. Krop, H. Borghaei, et al. · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  111. Abstract LBA4110LBA2026-09-05 · 21:45 CT · S406
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-268
    S. Tolaney, H. Rugo, C. Saura, et al. · MD Anderson Cancer Center
    Late-Breaking Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  112. Abstract 67922026-09-05 · 15:45 CT · S406
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-37
    A. Spira, C. Robert, C. Saura, et al. · Karolinska Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  113. Abstract 63872026-09-05 · 15:45 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-414
    M. Krop, S. Tolaney, S. Antonia, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.